Literature DB >> 11753983

Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.

L E Heyneman1, J E Herndon, P C Goodman, E F Patz.   

Abstract

BACKGROUND: Recently, there has been increased interest in the use of computed tomography (CT) for lung carcinoma screening. For this technique to be effective, small tumors must be detected at an earlier stage than large lesions. However, to the authors's knowledge, the relationship between the size of small primary (< or = 3 cm) neoplasms and disease stage at presentation has never been established clearly. The current study was performed to determine whether smaller lesions indeed have an earlier stage distribution compared with larger tumors.
METHODS: The Duke University Medical Center Tumor Registry identified 620 patients (261 women and 359 men, with a mean age of 67 years) who presented with pathologically proven primary nonsmall cell lung carcinomas measuring < or = 3 cm between 1980-1999. Surgical, pathologic, and imaging information was reviewed retrospectively to confirm the size of the lesion and the disease stage at the time of presentation. The distribution of tumor size within each stage and the distribution of disease stage according to tumor size were determined.
RESULTS: Tumors occurring in patients with TNM Stage IIIB disease were slightly larger than those found in patients with either more advanced or less advanced disease. However, there was no apparent statistically significant relation between the stage distribution and the size of the primary lesion.
CONCLUSIONS: The current study data did not find a statistically significant relation between the size of small primary lung tumors and the distribution of disease stage at the time of presentation. This finding suggests that the detection of small tumors using screening CT may not result in a shift to an earlier disease stage distribution. A reduction in mortality needs to be demonstrated by appropriate clinical trials prior to the initiation of mass CT screening programs. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11753983     DOI: 10.1002/1097-0142(20011215)92:12<3051::aid-cncr10106>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Lung cancer screening.

Authors:  Peter J Mazzone; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

2.  Video-assisted thoracoscopic surgery for stage I non-small cell lung cancer: long-term survival and prognostic factors.

Authors:  Xinguo Xiong; Wenlong Shao; Weiqiang Yin; Xin Xu; Hanzhang Chen; Yuan Qiu; Jianxing He
Journal:  Tumour Biol       Date:  2013-12

3.  Long-term survival outcomes of video-assisted thoracic surgery for patients with non-small cell lung cancer.

Authors:  Wenlong Shao; Xinguo Xiong; Hanzhang Chen; Jun Liu; Weiqiang Yin; Shuben Li; Xin Xu; Xin Zhang; Jianxing He
Journal:  Chin J Cancer Res       Date:  2014-08       Impact factor: 5.087

4.  Relationship between tumor size and disease stage in non-small cell lung cancer.

Authors:  Fu Yang; Haiquan Chen; Jiaqing Xiang; Yawei Zhang; Jianhua Zhou; Hong Hu; Jie Zhang; Xiaoyang Luo
Journal:  BMC Cancer       Date:  2010-09-02       Impact factor: 4.430

Review 5.  Lung cancer screening.

Authors:  Mylene T Truong; Reginald F Munden
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

6.  Defining Resistance and Tolerance to Cancer.

Authors:  Adler R Dillman; David S Schneider
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

Review 7.  Lung cancer screening with CT.

Authors:  Denise R Aberle; Kathleen Brown
Journal:  Clin Chest Med       Date:  2008-03       Impact factor: 2.878

8.  Factors Associated With Small Aggressive Non-Small Cell Lung Cancers in the National Lung Screening Trial: A Validation Study.

Authors:  Matthew T Warkentin; Martin C Tammemägi; Matthew T Freedman; Lawrence R Ragard; William G Hocking; Paul A Kvale; Darren R Brenner; Ping Hu; Thomas L Riley; John Commins; Timothy R Church; Christine D Berg
Journal:  JNCI Cancer Spectr       Date:  2018-01-31

9.  Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis.

Authors:  Xiangyu Zhao; Yuxing Chen; Xiaoqin Sun; Zaoke He; Tao Wu; Chenxu Wu; Jing Chen; Jinyu Wang; Kaixuan Diao; Xue-Song Liu
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

10.  Molecular Pathogenesis of Gene Regulation by the miR-150 Duplex: miR-150-3p Regulates TNS4 in Lung Adenocarcinoma.

Authors:  Shunsuke Misono; Naohiko Seki; Keiko Mizuno; Yasutaka Yamada; Akifumi Uchida; Hiroki Sanada; Shogo Moriya; Naoko Kikkawa; Tomohiro Kumamoto; Takayuki Suetsugu; Hiromasa Inoue
Journal:  Cancers (Basel)       Date:  2019-04-30       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.